The proven science behind real results

Over two decades of clinical research.

Our research covers a range of demographics over 14 clinical trials. Supported by government funding, our formulations have demonstrated consistent efficacy across urinary health endpoints.

It’s the evidence that sets us apart

Unlike some natural products, our efficacy is clinically documented.

Seipel Group has invested in extensive research to validate the effectiveness of our proprietary formulations. Our studies assess outcomes including urinary frequency, urgency, stress and urge incontinence, pad use, and bedwetting — all measured using validated tools and clinical endpoints.

14 clinical trials (published & unpublished)

Multiple randomized, double-blind, placebo-controlled studies

7 international Innovation & Efficacy Awards

Government-funded Research

90% of Participants Reported Improvement*

Results Measurable Within 2-8 Weeks

Clinical Research Timeline

More than two decades of progressive development and validation.

1999

Formulation Developed and Launched

Initial bladder health formulation developed and launched in Australia, based on traditional herbal ingredients with empirical evidence of urinary benefit.

2002

Steels et al., Australian Clinical Journal:

Pilot study investigates the effects of Crateva nurvala and Equisetum arvense (horsetail) in individuals with bladder control issues. Results demonstrate symptom improvements in a practitioner-led setting.

2004

Product Reformulation

Product reformulated based on practitioner feedback and observational data to improve clinical effectiveness.

2006

Schauss et al., FASEB Conference Abstract

Randomised, double-blind, placebo-controlled trial (n=120) confirms significant improvement in urinary frequency, urgency, nocturia, and both urge and stress incontinence. Study conducted on a Crateva-horsetail formulation.

2010

Further Formula Refinements

Further formula refinements introduced to increase efficacy onset and reduce the daily dosage from four capsules to two. Adjustments also reduced required treatment time from 12 to 4 weeks.

2011

Seipel et al., Unpublished Pilot Studies

Trials on the updated Urox® formulation demonstrate substantial reductions in overactive bladder symptoms and urinary incontinence.

2012

Seipel et al., Unpublished

Integration of Lindera aggregata into the Urox® formulation results in faster clinical improvements than previous iterations using Crateva and horsetail alone.

2018

Schoendorfer et al.

Peer-reviewed publication of a large-scale RCT (n=150) on Urox®. Demonstrates statistically significant reductions in daytime frequency, nocturia, urgency, urge incontinence, and stress incontinence. Efficacy observed within 2–4 weeks of daily use. Published in BMC Complementary Medicine and Therapies.

2021

Schloss et al.

Randomised, placebo-controlled trial on Urox® Junior shows a 62% reduction in nocturnal enuresis in children. Outcomes also include improved daytime bladder control. Published in Complementary Therapies in Medicine.

2022

Corrigendum to Schloss et al.

Confirms the reliability of findings and clarifies methodology and endpoint interpretation.

2022

Zapala et al.

Peer-reviewed, placebo-controlled trial assessing the mechanism of action of Urox®. Demonstrates that Urox® is potent in its ability to reverse 15 cystometric and biochemical parameters that are determinants of overactive bladder. Published in Frontiers in Molecular Bioscience.